BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8583583)

  • 1. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
    Humphrey PA; Keetch DW; Smith DS; Shepherd DL; Catalona WJ
    J Urol; 1996 Mar; 155(3):816-20. PubMed ID: 8583583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
    Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
    J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
    Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
    J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
    Loeb S; Gonzalez CM; Roehl KA; Han M; Antenor JA; Yap RL; Catalona WJ
    J Urol; 2006 Mar; 175(3 Pt 1):902-6. PubMed ID: 16469576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do clinically insignificant tumors of the prostate exist?
    Stamatiou K; Alevizos A; Mariolis A; Spiliopoulou C; Alevizou A; Bovis K; Sofras F
    Urol Int; 2008; 81(4):379-82. PubMed ID: 19077395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
    Soh S; Kattan MW; Berkman S; Wheeler TM; Scardino PT
    J Urol; 1997 Jun; 157(6):2212-8. PubMed ID: 9146618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
    Djavan B; Mazal P; Zlotta A; Wammack R; Ravery V; Remzi M; Susani M; Borkowski A; Hruby S; Boccon-Gibod L; Schulman CC; Marberger M
    Prostate; 2001 May; 47(2):111-7. PubMed ID: 11340633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
    Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
    Noguchi M; Stamey TA; Neal JE; Yemoto CE
    J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.
    Antenor JA; Han M; Roehl KA; Nadler RB; Catalona WJ
    J Urol; 2004 Jul; 172(1):90-3. PubMed ID: 15201744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?
    Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Pallwein L; Mitterberger M; Steiner E; Bartsch G; Horninger W
    BJU Int; 2008 Jul; 102(1):24-7. PubMed ID: 18341623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
    Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
    J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
    Datta MW; Dhir R; Dobbin K; Bosland MC; Melamed J; Becich MJ; Orenstein JM; Kajdacsy-Balla AA; Patel A; Macias V; Berman JJ
    J Urol; 2005 May; 173(5):1546-51. PubMed ID: 15821483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Djavan B; Ravery V; Zlotta A; Dobronski P; Dobrovits M; Fakhari M; Seitz C; Susani M; Borkowski A; Boccon-Gibod L; Schulman CC; Marberger M
    J Urol; 2001 Nov; 166(5):1679-83. PubMed ID: 11586201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.